Monitor the October and November 2026 medical meeting presentations for longer-term efficacy and safety data on obexelimab in IgG4-RD, and watch for Phase 2 SunStone topline results in SLE expected in Q4 2026, which could serve as a near-term catalyst.
Price Chart
Executive Summary
Zenas BioPharma announced upcoming presentations of new data from the Phase 3 INDIGO open-label extension of obexelimab in IgG4-RD at two scientific meetings in October and November 2026. The presentations cover longer-term flare protection, safety, glucocorticoid-associated toxicity, and vaccine responses. The company also guided for Phase 2 SunStone topline results in SLE in Q4 2026.
Key Facts
- New data from Phase 3 INDIGO open-label extension of obexelimab in IgG4-RD to be presented at 6th International Symposium on IgG4-RD (Oct 8-10) and ACR Convergence 2026 (Nov 6-11).
- Presentations include longer-term flare protection, safety, glucocorticoid-associated toxicity reduction, and vaccine responses.
- Phase 2 SunStone trial in SLE topline results expected in Q4 2026.
- Obexelimab is a bifunctional monoclonal antibody targeting CD19 and FcγRIIb, evaluated in 9 trials with 667 subjects.
- IgG4-RD affects approximately 20,000 diagnosed patients in the US, with estimated true prevalence near 40,000.
Financial Impact
No financial figures disclosed; clinical data readouts are non-financial catalysts.
Risk Factors
- Clinical data from INDIGO OLE may not show sustained benefit or may reveal safety concerns.
- Phase 2 SunStone SLE results are binary and could disappoint, given the competitive landscape.
- Reliance on WuXi Biologics for manufacturing and InnoCare as partner introduces geopolitical supply chain risk.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3366153 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | SC 13G | $27.09 | awaiting T+60 | — | $27.24 (+0.55%) |
Oct 16, 2026 11d ago | Press Release | $26.71 | awaiting T+60 | — | $27.24 (+1.98%) |
Oct 13, 2026 14d ago | 8-K | $25.16 | awaiting T+60 | — | $27.24 (+8.27%) |
Sep 22, 2026 5w ago | Press Release | $33.05 | awaiting T+60 | — | $27.24 (−17.58%) |
Sep 18, 2026 5w ago | Press Release | $32.55 | awaiting T+60 | — | $27.24 (−16.31%) |
Sep 11, 2026 6w ago | S-3ASR | $31.91 | awaiting T+60 | — | $27.24 (−14.63%) |
May 28, 2026 21w ago | Press Release | $18.56 $32.29 | ▲ +73.98% | ▲ +72.24% | $27.24 (+46.77%) |
May 19, 2026 23w ago | Press Release | $17.84 $29.20 | ▲ +63.68% | ▲ +57.39% | $27.24 (+52.69%) |
May 13, 2026 23w ago | Press Release | $19.93 $32.43 | ▲ +62.72% | ▲ +58.28% | $27.24 (+36.68%) |
May 13, 2026 23w ago | 8-K | $19.93 $32.43 | ▲ +62.72% | ▲ +58.28% | $27.24 (+36.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers